Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience
Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) is difficult in older patients with comorbidities and high-risk disease factors. Venetoclax, the first-in-class Bcl-2 inhibitor, has proven efficacy and safety in combination with azacytidine for treatment of hig...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
格式: | 圖書 |
出版: |
Frontiers Media S.A.,
2022-12-01T00:00:00Z.
|
主題: | |
在線閱讀: | Connect to this object online. |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
因特網
Connect to this object online.3rd Floor Main Library
索引號: |
A1234.567 |
---|---|
復印件 1 | 可用 |